Adam Dicker, Chief Medical Officer of OncoHost and Senior Vice President, Enterprise Radiation Oncology at Thomas Jefferson University Hospitals, shared a post on LinkedIn about a paper he co-authored with colleagues published in Cancer:
“We are thrilled to have our paper published, ‘Validation of the Functional Assessment of CancerTherapy – Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17)’.
We have validated the FACT-ICM-17, a concise patient-reported outcome measure assessing immune-related adverse events in cancer patients treated with immune checkpoint modulators.
The validated measure is now ready for implementation in clinical trials and routine patient care to improve monitoring and management of immunotherapy side effects. Thank you to the Prostate Cancer Foundation and the National Cancer Institute (NCI).”
Title: Validation of the Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical care
Authors: Lisa M. Gudenkauf, Danielle B. Tometich, Aasha I. Hoogland, Xiaoyin Li, Kedar Kirtane, Brent J. Small, Anna Barata, Brian D. Gonzalez, K. D. Jacobs, Christine H. Chung, Michael R. Shafique, Jhanelle Gray, Nikhil I. Khushalani, Michael A. Postow, David Cella, Kimberly A. Webster, Adam P. Dicker, and Heather S. L. Jim
You can read the Full Article in Cancer.
More posts featuring Adam Dicker.